| Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies.Rheumatology (Oxford) | PMID 33822898PMC8566200 | 2021-Nov-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of a 3-Antigen (Pre-S1/Pre-S2/S) Hepatitis B Vaccine: Results of a Phase 3 Randomized Clinical Trial in the Russian Federation.Clin Infect Dis | PMID 33119068PMC8563202 | 2021-Nov-02 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice.Hum Vaccin Immunother | PMID 34406911PMC8828160 | 2021-Nov-02 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| A phase III randomized, open-label, non-inferiority clinical trial comparing liquid and lyophilized formulations of oral live attenuated human rotavirus vaccine (HRV) in Indian infants.Hum Vaccin Immunother | PMID 34428112PMC8828117 | 2021-Nov-02 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and Immunogenicity of a novel three-dose recombinant nanoparticle rabies G protein vaccine administered as simulated post exposure immunization: A randomized, comparator controlled, multicenter, phase III clinical study.Hum Vaccin Immunother | PMID 34499574PMC8828110 | 2021-Nov-02 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Optimizing Treatment in Intermediate-Risk Prostate Cancer: Secondary Analysis of a Randomized Phase 3 Trial.Int J Radiat Oncol Biol Phys | PMID 33901566无 PMCID | 2021-Nov-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Phase 3 Randomized Trial of Topical Steroid Versus Placebo for Prevention of Radiation Dermatitis in Patients With Head and Neck Cancer Receiving Chemoradiation.Int J Radiat Oncol Biol Phys | PMID 34102298无 PMCID | 2021-Nov-01 | 0.95 | The record describes a phase 3 randomized trial evaluating a drug intervention (topical steroid) in an oncology setting, but the primary efficacy endpoint is the frequency (incidence) of radiation dermatitis, which is a categorical toxicity outcome, not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS). No time-to-event analysis (Kaplan-Meier, HR) is mentioned. Therefore, it does not meet the criterion for a primary/key secondary time-to-event efficacy endpoint. | 待处理 |
| Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001.J Clin Oncol | PMID 34228505无 PMCID | 2021-Nov-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.J Clin Oncol | PMID 34310172PMC8547923 | 2021-Nov-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial.JAMA Cardiol | PMID 34319398PMC8576587 | 2021-Nov-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Phase 3 Trials of Enhanced Versus Usual Care Physical Therapy for Patients at Risk of Poor Outcome Following Knee Arthroplasty: A Perspective on Meaning and a Way Forward.Phys Ther | PMID 34331766PMC8565332 | 2021-Nov-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Improved survival for young acute leukemia patients following a new donor hierarchy for allogeneic hematopoietic stem cell transplantation: A phase III randomized controlled study.Am J Hematol | PMID 34370319无 PMCID | 2021-Nov-01 | 0.85 | Eligible study meets oncology, human, randomized, Phase III, time-to-event, and original result criteria, but is excluded because it lacks a drug intervention. The study evaluates donor selection hierarchies for stem cell transplantation, which is a procedure/transplant intervention, not a pharmacological drug therapy as required for inclusion. | 待处理 |
| Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer.Clin Cancer Res | PMID 34380637PMC9401509 | 2021-Nov-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III InnovateTM Trial.Clin Cancer Res | PMID 34380643PMC9401517 | 2021-Nov-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor.Am J Hematol | PMID 34390504无 PMCID | 2021-Nov-01 | 0.85 | The study is a randomized Phase III trial with time-to-event endpoints, but the intervention (low-dose thymoglobulin) is an immunosuppressive agent for preventing graft-versus-host disease, not a drug for treating the underlying cancer (acute leukemia). Therefore, it does not meet the required drug intervention criterion for an oncology Kaplan-Meier cohort. | 待处理 |
| Targeting Depressive Symptoms in Younger Breast Cancer Survivors: The Pathways to Wellness Randomized Controlled Trial of Mindfulness Meditation and Survivorship Education.J Clin Oncol | PMID 34406839PMC8547916 | 2021-Nov-01 | 0.85 | The study is a randomized, Phase III clinical trial in breast cancer survivors with a primary efficacy endpoint of change in depressive symptoms. It does not involve a drug-containing intervention (interventions are mindfulness meditation and survivorship education) and does not report a time-to-event efficacy endpoint (OS, PFS, DFS, etc.). | 待处理 |
| Pharmacokinetics and Safety of Ceftobiprole in Pediatric Patients.Pediatr Infect Dis J | PMID 34533489PMC8505155 | 2021-Nov-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial.JAMA Oncol | PMID 34554208PMC8461552 | 2021-Nov-01 | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 待处理 |
| Evaluation of Mucosamin Effect on Treating Radiation Induced Oral Mucositis during and after Radiotherapy amongst Patients with Oral Cavity Squamous Cell Carcinoma.Asian Pac J Cancer Prev | PMID 34837931PMC9068180 | 2021-Nov-01 | 0.95 | The study is a randomized, phase III oncology trial with a drug intervention and reports primary efficacy results, but the key endpoint is a non-time-to-event outcome (severity of oral mucositis), failing the time-to-event criterion required for Kaplan-Meier digitization. | 待处理 |
| Licogliflozin versus placebo in women with polycystic ovary syndrome: A randomized, double-blind, phase 2 trial.Diabetes Obes Metab | PMID 34263971无 PMCID | 2021-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Antiperistaltic effect and safety of l-menthol oral solution on gastric mucosa for upper gastrointestinal endoscopy in Chinese patients: Phase III, multicenter, randomized, double-blind, placebo-controlled study.Dig Endosc | PMID 33527576PMC8596731 | 2021-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effects of Denosumab in Japanese Patients With Rheumatoid Arthritis Treated With Conventional Antirheumatic Drugs: 36-month Extension of a Phase III Study.J Rheumatol | PMID 33858976无 PMCID | 2021-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| What Does It Mean to Be a British Isles Lupus Assessment Group-Based Composite Lupus Assessment Responder? Post Hoc Analysis of Two Phase III Trials.Arthritis Rheumatol | PMID 33913260PMC8596929 | 2021-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Folic acid supplementation in postmenopausal women with hot flushes: phase III randomised double-blind placebo-controlled trial.BJOG | PMID 33982872无 PMCID | 2021-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Postoperative continuous positive airway pressure to prevent pneumonia, re-intubation, and death after major abdominal surgery (PRISM): a multicentre, open-label, randomised, phase 3 trial.Lancet Respir Med | PMID 34153272无 PMCID | 2021-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study.Cephalalgia | PMID 34171973PMC8592099 | 2021-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| EMA Review of Isatuximab in Combination with Pomalidomide and Dexamethasone for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma.Oncologist | PMID 34213061PMC8571773 | 2021-Nov | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study.Lancet Respir Med | PMID 34214475无 PMCID | 2021-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Levodopa-Carbidopa Intestinal Gel Reduces Dyskinesia in Parkinson's Disease in a Randomized Trial.Mov Disord | PMID 34236101PMC9292774 | 2021-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1-Selected NSCLC.J Thorac Oncol | PMID 34265434无 PMCID | 2021-Nov | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma.Future Oncol | PMID 34269067无 PMCID | 2021-Nov | 0.45 | The record describes a Phase III, randomized, drug-intervention trial in esophageal cancer, meeting core oncology, human, randomization, and phase criteria. However, the title and abstract do not explicitly report results for a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS) nor present Kaplan-Meier curves or hazard ratios. The document is identified as a protocol/rationale ('study described here'), not a formal result report. Therefore, is_eligible is set to null due to insufficient evidence for the time_to_event and original_result criteria. | 待处理 |
| The Posology of Dupilumab in Pediatric Patients With Atopic Dermatitis.Clin Pharmacol Ther | PMID 34270797PMC9290854 | 2021-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA.Future Oncol | PMID 34278827PMC8530153 | 2021-Nov | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and safety of onabotulinumtoxinA in patients with overactive bladder: subgroup analyses by sex and by serum prostate-specific antigen levels in men from a randomized controlled trial.Int Urol Nephrol | PMID 34292493PMC8494701 | 2021-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials.Eur J Neurol | PMID 34292643PMC9291872 | 2021-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study.Oncologist | PMID 34313371PMC8571742 | 2021-Nov | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Impact of UGT1A1 genotype on the efficacy and safety of irinotecan-based chemotherapy in metastatic colorectal cancer.Cancer Sci | PMID 34327766PMC8586680 | 2021-Nov | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia.Clin Lymphoma Myeloma Leuk | PMID 34334330PMC8568662 | 2021-Nov | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| CXCR4 and hif-1α as prognostic molecular markers for stage 3 colon cancer patients: post hoc analysis of the randomized, multicenter phase 3 PETACC-2 trial dataset.Acta Oncol | PMID 34355650无 PMCID | 2021-Nov | 0.99 | 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 | 待处理 |
| Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061.Gastric Cancer | PMID 34363528PMC8502140 | 2021-Nov | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib With Rituximab-Based Immunochemotherapy in Patients With Relapsed Indolent B-cell Lymphoma.Clin Lymphoma Myeloma Leuk | PMID 34389273PMC9407680 | 2021-Nov | 0.80 | The study is a Phase III randomized oncology trial in humans with a drug intervention, but it reports only safety run-in results and objective response rates (ORR), not a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, HR, Kaplan-Meier). Therefore, it does not meet the inclusion criteria for a Kaplan-Meier digitization cohort. | 待处理 |
| Randomized multicenter noninferiority phase III clinical trial of the first biosimilar of eculizumab.Ann Hematol | PMID 34398258PMC8510904 | 2021-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of arimoclomol in Niemann-Pick disease type C: Results from a double-blind, randomised, placebo-controlled, multinational phase 2/3 trial of a novel treatment.J Inherit Metab Dis | PMID 34418116PMC9293014 | 2021-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3).Future Oncol | PMID 34423676无 PMCID | 2021-Nov | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Inhaled isoflurane via the anaesthetic conserving device versus propofol for sedation of invasively ventilated patients in intensive care units in Germany and Slovenia: an open-label, phase 3, randomised controlled, non-inferiority trial.Lancet Respir Med | PMID 34454654无 PMCID | 2021-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: A randomised controlled trial (MPACA-3).Eur J Cancer | PMID 34464782无 PMCID | 2021-Nov | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 待处理 |
| Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial).Eur J Cancer | PMID 34507244无 PMCID | 2021-Nov | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Phase II, Double-Blind, Vehicle-Controlled Study to Determine the Cantharidin Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects with External Genital Warts.Am J Clin Dermatol | PMID 34515985PMC8436872 | 2021-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL).Gynecol Oncol | PMID 34521554无 PMCID | 2021-Nov | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial.Adv Ther | PMID 34542830PMC8523004 | 2021-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |